<scp>PD</scp> ‐ <scp>L1</scp> Expression and Histopathological Features in <scp>EGFR</scp> ‐Mutated Non‐Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After <scp>EGFR</scp> ‐Tyrosine Kinase Inhibitors Resistance
High PD-L1 expression in EGFRm NSCLC is associated with more aggressive morphologic features and modifies the association between post-progression ICI and survival. These findings support PD-L1-informed selection after EGFR-TKI failure, while prospective confirmation is needed.
Authors
- Hirofumi Chiba (ORCID: https://orcid.org/0000-0002-7033-3084)
- Takumi Ikeda (ORCID: https://orcid.org/0000-0003-0527-3078)
- Kotomi Arioka
- Taiki Ishigooka
- Yuichi Yamada
- Toshiyuki Sumi
- Keigo Matsuura
Institutions
- Sapporo Medical University (JP)
- Hakodate National Hospital (JP)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/1759-7714.70252
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00